Use of more costly diabetes medications varies widely

October 12, 2012
Use of more costly diabetes medications varies widely
Even within an integrated Veterans Affairs system with a uniform national formulary and established criteria for drug use, there is substantial variation in the use of thiazolidinediones and long-acting insulin analogues among veterans with type 2 diabetes mellitus, according to a research letter published online Oct. 8 in the Archives of Internal Medicine.

(HealthDay)—Even within an integrated Veterans Affairs (VA) system with a uniform national formulary and established criteria for drug use, there is substantial variation in the use of thiazolidinediones and long-acting insulin analogues among veterans with type 2 diabetes mellitus (T2DM), according to a research letter published online Oct. 8 in the Archives of Internal Medicine.

Walid Gellad, M.D., M.P.H., of the VA Pittsburgh Healthcare System, and colleagues conducted a study involving 1,158,809 veterans with T2DM to evaluate the use of high-cost thiazolidinediones (rosiglitazone, pioglitazone) and long-acting (detemir, glargine) in the fiscal year 2009.

The researchers found that 78.3 percent of the patients received prescriptions for diabetes medications: 66.7 percent received an oral medication, 27.7 percent received insulin, and 16.1 percent received both. Thiazolidinedione use ranged from 1.4 to 25.4 percent across the 139 facilities, with a median of 8.2 percent. The median adjusted percentage of patients receiving insulin who used long-acting analogues was 40.6 percent, but ranged from 4.0 to 71.2 percent.

"While some variation is expected given reasonable differences in prescribing practices, the observed 18-fold variation across facilities was unexpected," the authors write. "Our findings suggest that while they may exert powerful effects on medication choice, formularies and utilization management tools can only go so far in standardizing ."

Several authors are employees of the VA.

Explore further: Absolute incretin effect reduced in type 2 diabetes

More information: Full Text (subscription or payment may be required)

Related Stories

Absolute incretin effect reduced in type 2 diabetes

June 25, 2012
(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) the absolute incretin effect is reduced compared with healthy individuals, but its relative importance is increased, particularly in first-phase insulin secretion, ...

Thiazolidinedione use in patients with Type 2 diabetes may increase risk for diabetic macular edema

June 11, 2012
Treatment with glucose-lowering thiazolidinedione drugs in patients with Type 2 diabetes appears to be associated with an increased risk of diabetic macular edema (a complication that may affect vision) at 1-year and 10-year ...

Thiazolidinediones tied to lower cancer risk in diabetes patients

April 27, 2012
(HealthDay) -- Thiazolidinediones are associated with a lower risk of liver and colorectal cancer in patients with type 2 diabetes, according to a study published in the May issue of Hepatology.

Recommended for you

Pancreatic islets study may spur diabetes treatment advances

September 22, 2017
Investigators in the Vanderbilt Diabetes Research and Training Center (VDRTC) and collaborators at Stanford University have discovered new insights into the molecular mechanisms of cell proliferation in juvenile human pancreatic ...

Finding a natural defense against clogged arteries

September 20, 2017
In type 2 diabetes, chronic inflammation drives cardiovascular disease, the leading cause of death among people with the condition. Researchers at Joslin Diabetes Center now have identified an unexpected natural protective ...

Study identifies blood vessel as a therapeutic target for diabetes

September 14, 2017
Blood vessels have an often overlooked role of regulating the transfer of nutrients from the blood to organs in the body. In a new Yale-led study, researchers have identified a role of a secreted protein, apelin, in regulating ...

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients

September 14, 2017
A majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels, according to a new study published in The Lancet Diabetes ...

Could swine flu be linked to type 1 diabetes?

September 14, 2017
(HealthDay)—Young people who've been infected with the H1N1 swine flu virus may be at increased risk for type 1 diabetes, a new study suggests.

Epigenetic 'fingerprint' identifies diabetes risk

September 14, 2017
Deakin researchers have identified an epigenetic marker that predicts risk of type 2 diabetes in women with gestational diabetes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.